OncoMatch

OncoMatch/Clinical Trials/NCT06418789

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Is NCT06418789 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles ) for germ cell tumor.

Phase 2RecruitingN.N. Petrov National Medical Research Center of OncologyNCT06418789Data as of May 2026

Treatment: High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )This is a prospective, single-center, non-randomized phase II study. Patients with germ cell tumors of gonadal and extragonadal localization who have progressed after prior platinum-containing first-line chemotherapy will receive high-dose chemotherapy with TI (2 cycles) folollowed by high dose CE chemotherapy with autologous stem cell transplantation (3 cycles). The primary endpoint of the study is to evaluate the efficacy high-dose chemotherapy as second-line drug therapy for patients with advanced germ cell tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Testicular Germ Cell Tumor

Prior therapy

Max 1 prior line
Min 1 prior line

Must have received: platinum-based chemotherapy (BEP, EP) — first-line

Progression after 3 or 4 cycles of platinum-containing first-line chemotherapy (ВЕР or EP)

Cannot have received: any drug therapy for disseminated GO

Exception: ≤1 prior line allowed

Administration of ≥2 lines of prior drug therapy for disseminated GO

Lab requirements

Blood counts

Hemoglobin ≥ 90 g/L; neutrophils ≥ 1.5 x 10^9/L; platelets ≥ 75 x 10^9/L

Kidney function

creatinine ≥ 1.5 x HGH (or CKF ≤ 60 mL/min)

Liver function

ALT or AST ≥ 2.5 x HGN (5 x HGN for patients with liver metastases); bilirubin ≥ 1.5 x IUH (except for patients with Gilbert syndrome, in whom total bilirubin levels should not exceed 50 μmol/L); alkaline phosphatase ≥ 2.5 x IUH

Required Initial Laboratory Values: Hemoglobin ≥ 90 g/L; neutrophils ≥ 1.5 x 10^9/L; platelets ≥ 75 x 10^9/L; creatinine ≥ 1.5 x HGH (or CKF ≤ 60 mL/min); ALT or AST ≥ 2.5 x HGN (5 x HGN for patients with liver metastases); bilirubin ≥ 1.5 x IUH (except for patients with Gilbert syndrome, in whom total bilirubin levels should not exceed 50 μmol/L); alkaline phosphatase ≥ 2.5 x IUH.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify